GELS
Gelteq Limited Ordinary Shares
Drug Manufacturers - Specialty & Generic
Market Cap$5M
5Y Perf.-81.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
GELS vs DARE
Revenue, margins, valuation, and 5-year total return — side by side.
DARE
Daré Bioscience, Inc.
Biotechnology
Market Cap$25M
5Y Perf.-31.2%
GELS vs DARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GELS | DARE |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $5M | $25M |
| Revenue (TTM) | $148K | $-57K |
| Net Income (TTM) | $-4M | $-17M |
| Gross Margin | 100.0% | -1461.1% |
| Operating Margin | -87.7% | -2396.9% |
| Total Debt | $4M | $1M |
| Cash & Equiv. | $25K | $16M |
GELS vs DARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GELS
DARE
| Stock | Oct 24 | May 26 | Return |
|---|---|---|---|
| Gelteq Limited Ordi… (GELS) | 100 | 18.2 | -81.8% |
| Daré Bioscience, In… (DARE) | 100 | 68.8 | -31.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GELS vs DARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DARE leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Gelteq Limited Ordinary Shares is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
GELS
Gelteq Limited Ordinary Shares
The Long-Run Compounder
GELS is the clearest fit if your priority is long-term compounding.
- -84.1% 10Y total return vs DARE's -99.0%
- -27.4% margin vs DARE's -414.3%
- -19.5% ROA vs DARE's -56.8%
Best for: long-term compounding
DARE
Daré Bioscience, Inc.
The Income Pick
DARE carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.48
- Rev growth -99.7%, EPS growth 88.4%
- Lower volatility, beta 0.48, current ratio 0.85x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | DARE | -99.7% revenue growth vs GELS's -100.0% |
| Quality / Margins | GELS | -27.4% margin vs DARE's -414.3% |
| Stability / Safety | DARE | Beta 0.48 vs GELS's 1.16 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DARE | +0.7% vs GELS's -66.5% |
| Efficiency (ROA) | GELS | -19.5% ROA vs DARE's -56.8% |
GELS vs DARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
GELS vs DARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGELSLAGGINGDARE
DAREDaré Bioscience, Inc.
2leads
GELSGelteq Limited Ordina…
2leads
6 Total Categories
CATEGORYLEADERvs DAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GELS4/5
Valuation MetricsMultiples, price ratios, and targets
—
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GELS4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
DARE5/6
Risk & VolatilityBeta, volatility, and downside exposure
DARE2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
GELS leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
GELS and DARE operate at a comparable scale, with $147,535 and -$57,130 in trailing revenue. GELS is the more profitable business, keeping -27.4% of every revenue dollar as net income compared to DARE's -414.3%. On growth, GELS holds the edge at +100.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GELSGelteq Limited Or… | DAREDaré Bioscience, … |
|---|---|---|
| RevenueTrailing 12 months | $147,535 | -$57,130 |
| EBITDAEarnings before interest/tax | -$12M | -$16M |
| Net IncomeAfter-tax profit | -$4M | -$17M |
| Free Cash FlowCash after capex | -$2M | -$7M |
| Gross MarginGross profit ÷ Revenue | +100.0% | -1461.1% |
| Operating MarginEBIT ÷ Revenue | -87.7% | -2396.9% |
| Net MarginNet income ÷ Revenue | -27.4% | -414.3% |
| FCF MarginFCF ÷ Revenue | -12.4% | +492.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +100.0% | -94.6% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +49.2% |
GELS leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
Insufficient data to determine a leader in this category.
Valuation Metrics
| Metric | GELSGelteq Limited Or… | DAREDaré Bioscience, … |
|---|---|---|
| Market CapShares × price | $5M | $25M |
| Enterprise ValueMkt cap + debt − cash | $8M | $11M |
| Trailing P/EPrice ÷ TTM EPS | — | -6.06x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2587.71x |
| Price / BookPrice ÷ Book value/share | — | — |
| Price / FCFMarket cap ÷ FCF | — | 5.25x |
Insufficient data to determine a leader in this category.
Profitability & Efficiency
GELS leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
GELS delivers a -26.8% return on equity — every $100 of shareholder capital generates $-27 in annual profit, vs $-6 for DARE. On the Piotroski fundamental quality scale (0–9), DARE scores 4/9 vs GELS's 2/9, reflecting mixed financial health.
| Metric | GELSGelteq Limited Or… | DAREDaré Bioscience, … |
|---|---|---|
| ROE (TTM)Return on equity | -26.8% | -6.1% |
| ROA (TTM)Return on assets | -19.5% | -56.8% |
| ROICReturn on invested capital | -11.1% | — |
| ROCEReturn on capital employed | -15.5% | -36.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.25x | — |
| Net DebtTotal debt minus cash | $4M | -$14M |
| Cash & Equiv.Liquid assets | $24,522 | $16M |
| Total DebtShort + long-term debt | $4M | $1M |
| Interest CoverageEBIT ÷ Interest expense | -6.89x | -35.60x |
GELS leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
DARE leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DARE five years ago would be worth $1,757 today (with dividends reinvested), compared to $1,585 for GELS. Over the past 12 months, DARE leads with a +0.7% total return vs GELS's -66.5%. The 3-year compound annual growth rate (CAGR) favors DARE at -37.6% vs GELS's -45.9% — a key indicator of consistent wealth creation.
| Metric | GELSGelteq Limited Or… | DAREDaré Bioscience, … |
|---|---|---|
| YTD ReturnYear-to-date | -44.4% | +49.2% |
| 1-Year ReturnPast 12 months | -66.5% | +0.7% |
| 3-Year ReturnCumulative with dividends | -84.1% | -75.8% |
| 5-Year ReturnCumulative with dividends | -84.1% | -82.4% |
| 10-Year ReturnCumulative with dividends | -84.1% | -99.0% |
| CAGR (3Y)Annualised 3-year return | -45.9% | -37.6% |
DARE leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
DARE leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DARE is the less volatile stock with a 0.48 beta — it tends to amplify market swings less than GELS's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DARE currently trades 31.7% from its 52-week high vs GELS's 13.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GELSGelteq Limited Or… | DAREDaré Bioscience, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | 0.48x |
| 52-Week HighHighest price in past year | $3.51 | $9.19 |
| 52-Week LowLowest price in past year | $0.44 | $1.27 |
| % of 52W HighCurrent price vs 52-week peak | +13.3% | +31.7% |
| RSI (14)Momentum oscillator 0–100 | 24.0 | 70.2 |
| Avg Volume (50D)Average daily shares traded | 18K | 581K |
DARE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | GELSGelteq Limited Or… | DAREDaré Bioscience, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
GELS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DARE leads in 2 (Total Returns, Risk & Volatility).
Best OverallGelteq Limited Ordinary Sha… (GELS)Leads 2 of 6 categories
Loading custom metrics...
GELS vs DARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is GELS or DARE a better buy right now?
For growth investors, Daré Bioscience, Inc.
(DARE) is the stronger pick with -99. 7% revenue growth year-over-year, versus -100. 0% for Gelteq Limited Ordinary Shares (GELS). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GELS or DARE?
Over the past 5 years, Daré Bioscience, Inc.
(DARE) delivered a total return of -82. 4%, compared to -84. 1% for Gelteq Limited Ordinary Shares (GELS). Over 10 years, the gap is even starker: GELS returned -84. 1% versus DARE's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GELS or DARE?
By beta (market sensitivity over 5 years), Daré Bioscience, Inc.
(DARE) is the lower-risk stock at 0. 48β versus Gelteq Limited Ordinary Shares's 1. 16β — meaning GELS is approximately 143% more volatile than DARE relative to the S&P 500.
04Which is growing faster — GELS or DARE?
By revenue growth (latest reported year), Daré Bioscience, Inc.
(DARE) is pulling ahead at -99. 7% versus -100. 0% for Gelteq Limited Ordinary Shares (GELS). On earnings-per-share growth, the picture is similar: Gelteq Limited Ordinary Shares grew EPS 100. 0% year-over-year, compared to 88. 4% for Daré Bioscience, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GELS or DARE?
Gelteq Limited Ordinary Shares (GELS) is the more profitable company, earning -27.
4% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps -27. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GELS leads at -87. 7% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — GELS leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — GELS or DARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is GELS or DARE better for a retirement portfolio?
For long-horizon retirement investors, Daré Bioscience, Inc.
(DARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48)). Both have compounded well over 10 years (DARE: -99. 0%, GELS: -84. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between GELS and DARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(GELS: 100.0% · DARE: -94.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.